undamentalytics Newsletter
Sign in

Abbott Laboratories cash flow statement

In fiscal 2025, Abbott Laboratories's operations generated $9.57bn of cash; it spent $2.17bn on capital projects, leaving free cash flow of $7.39bn. It returned $4.12bn in dividends and $893m through buybacks.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations7.38.79.09.33.33.73.03.25.66.36.17.910.59.67.38.69.69.9
Depreciation and amortisation1.21.21.41.40.90.90.90.81.01.11.11.21.51.31.31.31.41.5
Stock-based pay0.40.40.40.40.30.20.30.30.40.50.50.50.60.70.60.70.70.7
Capital spending1.11.01.51.81.11.11.11.11.11.41.62.21.91.82.22.22.22.1
Free cash flow6.27.77.57.52.22.61.92.14.44.94.55.78.67.85.16.47.47.8
Free cash flow after stock pay5.87.37.17.11.92.41.61.84.04.44.05.28.07.14.45.76.77.1
Dividends paid2.42.72.93.20.91.31.41.51.82.02.32.63.23.33.63.84.14.3
Share buybacks0.80.90.12.41.62.22.20.50.10.20.70.42.33.81.21.30.91.8

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABT vs MDTABT vs SYKABT vs GEHC

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Abbott Laboratories's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abbott Laboratories.